Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11228283 | 0.98 | CYP19A1 (0.65) | CYP19A1HDAC1HDAC6CYP1A2CYP3A4 | |
| SCHEMBL15804428 | 0.95 | CYP19A1 (0.61) | CYP19A1HDAC1HDAC6CYP1A2CYP3A4 | |
| SCHEMBL17159812 | 0.90 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL309621 | 0.85 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP3A4UGT1A4 | |
| SCHEMBL15688800 | 0.84 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL14496521 | 0.83 | CYP19A1 (0.57) | CYP19A1HDAC1HDAC6CYP1A2CYP3A4 | |
| SCHEMBL11354103 | 0.82 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6CYP3A4CYP11B1 | |
| SCHEMBL3235365 | 0.82 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL10066395 | 0.81 | HDAC1 (0.60) | CYP19A1HDAC1HDAC6CYP1A2CYP3A4 | |
| SCHEMBL307542 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2922840-B1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2490692-B1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| CN-1910158-A | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole | WYETH CORP (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1709003-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | Wyeth (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073198-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE | WYETH (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050171180-A1 | Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-4315017-A | Triazole derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-09 | — | — | US | disclosed |
| EP-0008651-B1 | DERIVATIVES OF TRIAZOLE, PROCESS FOR THEIR PRODUCTION AND INSECTICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1981-10-14 | — | — | EP | disclosed |
| EP-0008651-A1 | Derivatives of triazole, process for their production and insecticides containing them | BASF Aktiengesellschaft (DE) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | CYP19A1 2930/4885HDAC1 797/4885HDAC6 796/4885 |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | CYP19A1 3608/4885HDAC1 1720/4885HDAC6 1595/4885 |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | KCNJ11, KCNJ1, KCNJ8 | CYP19A1 3608/4885HDAC1 1720/4885HDAC6 1595/4885 |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | CYP19A1 389/4885HDAC1 1536/4885HDAC6 3062/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CYP19A1 2396/4885HDAC1 233/4885HDAC6 553/4885 |
| US-20050171180-A1 | Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole | IAPP, APP, CBR3 | CYP19A1 1070/4885HDAC1 3987/4885HDAC6 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.